183129-88-6

Upstream product

• 183129-84-2 4-(4'-n-octylphenyl)butan-1-ol 
• 2189-60-8 Octylbenzene 
• 207132-59-0 4-(4-octyl-phenyl)-butyric acid 
• 64779-10-8 4-(4-octyl-phenyl)-4-oxo-butyric acid 

Downstream Products

• 183129-96-6 {2-Amino-5-[2-(4-octyl-phenyl)-ethyl]-thiophen-3-yl}-(2-chloro-phenyl)-methanone 
• 876391-68-3 2-methylene-4-(4'-octylphenyl)butanal 
• 1026030-36-3 [5-(2-Chloro-phenyl)-7-[2-(4-octyl-phenyl)-ethyl]-1,3-dihydro-thieno[2,3-e][1,4]diazepin-(2Z)-ylidene]-hydrazine 
• 1026656-39-2 N-{3-(2-Chloro-benzoyl)-5-[2-(4-octyl-phenyl)-ethyl]-thiophen-2-yl}-2-iodo-acetamide 
• 183130-03-2 2-Chloro-N-{3-(2-chloro-benzoyl)-5-[2-(4-octyl-phenyl)-ethyl]-thiophen-2-yl}-acetamide 
• 183130-14-5 2-Amino-N-{3-(2-chloro-benzoyl)-5-[2-(4-octyl-phenyl)-ethyl]-thiophen-2-yl}-acetamide 
• 122854-29-9 5-(2-Chloro-phenyl)-7-[2-(4-octyl-phenyl)-ethyl]-1,3-dihydro-thieno[2,3-e][1,4]diazepin-2-one 

Relevant academic research and scientific papers

Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720

The first enantioselective synthesis of chiral isosteric phosphonate analogues of FTY720 is described. One of these analogues, FTY720-(E)- vinylphosphonate (S)-5, but not its R enantiomer, elicited a potent antiapoptotic effect in intestinal epithelial ce

Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: Pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system

A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (±)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]- 6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.